Cargando…

Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney

BACKGROUND: Hepatotoxicity due to drugs is the most common cause of deaths. Nephrotoxicity of the drugs is usually associated with the drugs accumulation in renal tissue. Paromomycin sulfate (PMS) is an anti-leishmania drug. Although the topical approach for the treatment of leishmania is attractive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalantari, Heibatullah, Hemmati, Ali Asghar, Bavarsad, Neda, Rezaie, Annahita, Ahmadi, Shahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: DOCS 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302405/
https://www.ncbi.nlm.nih.gov/pubmed/25625051
_version_ 1782353791447728128
author Kalantari, Heibatullah
Hemmati, Ali Asghar
Bavarsad, Neda
Rezaie, Annahita
Ahmadi, Shahin
author_facet Kalantari, Heibatullah
Hemmati, Ali Asghar
Bavarsad, Neda
Rezaie, Annahita
Ahmadi, Shahin
author_sort Kalantari, Heibatullah
collection PubMed
description BACKGROUND: Hepatotoxicity due to drugs is the most common cause of deaths. Nephrotoxicity of the drugs is usually associated with the drugs accumulation in renal tissue. Paromomycin sulfate (PMS) is an anti-leishmania drug. Although the topical approach for the treatment of leishmania is attractive, its use might cause nephrotoxicity and hepatotoxicity. OBJECTIVES: This study aimed to evaluate probable nephrotoxicity and hepatotoxicity of topically administered PMS liposomes. MATERIALS AND METHODS: Nine groups of male rats were used in this study; each group consisted of 6 rats that were evaluated in 3 time periods of 10, 20, and 30 days. Three groups were placed in each time period; a control group did not receive any medicine; a negative control group received liposome without paromomycin sulfate; and a positive control group received nanoliposomal formulations containing paromomycin sulfate. Pharmaceutical formulation (topical form) was used 2 times a day in a 12-hour interval. At the end of the period, hepatic enzymes (ALT, AST, and ALK), BUN levels, and serum creatinine were measured. RESULTS: The results showed that no significant change was occurred in the amount of the above factors compared with the control group with the negative control group in 3 time periods (P > 0.05). The histopathological results of the liver and kidney showed that there was no difference in the between the negative control and positive control groups and the control group in the 10- and 20-day periods, and they had a normal structure. However, after the 30-day time period a reversible cellular inflammation in the liver and mild kidney necrosis was seen in the positive control group versus the control and negative control groups. CONCLUSIONS: In general, it can be said that the application of nanoliposomal paromomycin sulfate formulations for topical treatment of the cutaneous leishmaniasis does not create serious side effects in the short term, but its long-term use leads to mild renal and liver side effects that requires more attention.
format Online
Article
Text
id pubmed-4302405
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher DOCS
record_format MEDLINE/PubMed
spelling pubmed-43024052015-01-26 Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney Kalantari, Heibatullah Hemmati, Ali Asghar Bavarsad, Neda Rezaie, Annahita Ahmadi, Shahin Jundishapur J Nat Pharm Prod Research Article BACKGROUND: Hepatotoxicity due to drugs is the most common cause of deaths. Nephrotoxicity of the drugs is usually associated with the drugs accumulation in renal tissue. Paromomycin sulfate (PMS) is an anti-leishmania drug. Although the topical approach for the treatment of leishmania is attractive, its use might cause nephrotoxicity and hepatotoxicity. OBJECTIVES: This study aimed to evaluate probable nephrotoxicity and hepatotoxicity of topically administered PMS liposomes. MATERIALS AND METHODS: Nine groups of male rats were used in this study; each group consisted of 6 rats that were evaluated in 3 time periods of 10, 20, and 30 days. Three groups were placed in each time period; a control group did not receive any medicine; a negative control group received liposome without paromomycin sulfate; and a positive control group received nanoliposomal formulations containing paromomycin sulfate. Pharmaceutical formulation (topical form) was used 2 times a day in a 12-hour interval. At the end of the period, hepatic enzymes (ALT, AST, and ALK), BUN levels, and serum creatinine were measured. RESULTS: The results showed that no significant change was occurred in the amount of the above factors compared with the control group with the negative control group in 3 time periods (P > 0.05). The histopathological results of the liver and kidney showed that there was no difference in the between the negative control and positive control groups and the control group in the 10- and 20-day periods, and they had a normal structure. However, after the 30-day time period a reversible cellular inflammation in the liver and mild kidney necrosis was seen in the positive control group versus the control and negative control groups. CONCLUSIONS: In general, it can be said that the application of nanoliposomal paromomycin sulfate formulations for topical treatment of the cutaneous leishmaniasis does not create serious side effects in the short term, but its long-term use leads to mild renal and liver side effects that requires more attention. DOCS 2014-10-26 /pmc/articles/PMC4302405/ /pubmed/25625051 Text en Copyright © 2014, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences; Published by DOCS. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Kalantari, Heibatullah
Hemmati, Ali Asghar
Bavarsad, Neda
Rezaie, Annahita
Ahmadi, Shahin
Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title_full Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title_fullStr Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title_full_unstemmed Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title_short Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney
title_sort effect of topical nanoliposomes of paromomycin on rats liver and kidney
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302405/
https://www.ncbi.nlm.nih.gov/pubmed/25625051
work_keys_str_mv AT kalantariheibatullah effectoftopicalnanoliposomesofparomomycinonratsliverandkidney
AT hemmatialiasghar effectoftopicalnanoliposomesofparomomycinonratsliverandkidney
AT bavarsadneda effectoftopicalnanoliposomesofparomomycinonratsliverandkidney
AT rezaieannahita effectoftopicalnanoliposomesofparomomycinonratsliverandkidney
AT ahmadishahin effectoftopicalnanoliposomesofparomomycinonratsliverandkidney